WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that Thomas E. Griffin has joined the company as chief financial officer (CFO). Mr. Griffin has more than 25 years of executive management experience at emerging growth medical technology companies. He brings a track record of success, leading both early-stage and commercial companies throughout his career.
“Tom’s financial acumen combined with his significant experience in the medical technology industry for both private and publicly held companies will be a tremendous asset to Avedro and we are very pleased that he has decided to join us in this important executive role,” said Reza Zadno, Ph.D., chief executive officer, Avedro, Inc. “We look forward to leveraging his proven expertise to lead Avedro’s finance functions for high growth and future financing options. Tom’s guidance will be indispensable as we continue to expand our ability to deliver innovative products that dramatically improve the lives of patients with keratoconus and develop new and innovative cross-linking applications that help reduce the need for eyeglasses and contact lenses.”
A veteran finance executive, Mr. Griffin has spent his entire career in financial operations at medical technology and biotechnology companies. For 10 years and during the company’s initial public offering, Mr. Griffin served as CFO of Entellus Medical, Inc. (NASDAQ: ENTL), a medical technology company that designs products for the treatment of chronic and recurrent sinusitis, before transitioning to vice president of finance in May 2016. Prior to this, Mr. Griffin served in a variety of executive level financial positions at several organizations, including Digital Gene Technologies, Inc., Centerpulse Spine-Tech, Inc. (now Zimmer Spine, Inc.), and CIMA Labs Inc. (now owned by Teva Pharmaceutical Industries Ltd.). He is a member of Helius Medical Technologies, Inc.’s board of directors, where he is chairperson of the audit committee. Mr. Griffin holds a B.A. in Accounting from the University of Minnesota, Duluth, an M.B.A. in Management from the University of St. Thomas, and is a certified public accountant (inactive).
“This is a very exciting time for Avedro, and I look forward to working with the team to achieve the company’s strategic and financial growth objectives,” said Mr. Griffin.
About Avedro, Inc.
Avedro is a privately held pharmaceutical
and medical device company advancing the science and technology of
corneal cross-linking and refractive correction. Avedro’s Photrexa®
Viscous, Photrexa® and KXL® products are approved
for sale in the United States. Avedro’s products sold outside of the
United States include capital equipment such as the UV-X devices, the
KXL and Mosaic™ Systems, and related proprietary pharmaceuticals such as
the VibeX® and MedioCROSS® formulations.
Avedro distributes its products in countries outside of the United
States through a network of ophthalmic medical device distributors.
MA-00702A
